List of Excipients in Branded Drug OSMITROL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	OSMITROL	mannitol	0338-0351	HYDROCHLORIC ACID
Baxter Healthcare Corporation	OSMITROL	mannitol	0338-0351	SODIUM HYDROXIDE
Baxter Healthcare Corporation	OSMITROL	mannitol	0338-0351	WATER
Baxter Healthcare Company	OSMITROL	mannitol	0338-0353	HYDROCHLORIC ACID
Baxter Healthcare Company	OSMITROL	mannitol	0338-0353	SODIUM HYDROXIDE
Baxter Healthcare Company	OSMITROL	mannitol	0338-0353	WATER

OSMITROL Excipient Strategy and Commercial Opportunities for Mannitol Injection

Last updated: August 7, 2026

OSMITROL is a preservative-free intravenous mannitol product used as an osmotic diuretic to reduce intracranial and intraocular pressure and promote urinary excretion. Its excipient strategy is unusually simple: mannitol is the active pharmaceutical ingredient and the formulation is primarily an aqueous solution of mannitol in Water for Injection, with pH adjustment as needed. Commercial differentiation therefore depends less on novel excipients than on crystallization control, container performance, concentration flexibility, storage reliability, supply continuity, and hospital workflow.

What is OSMITROL and what excipients does it contain?

OSMITROL is a sterile solution of mannitol for intravenous administration. Baxter Healthcare Corporation markets the product in multiple concentrations and container formats. The labeled product is preservative-free and intended for single-dose use.[1]

OSMITROL composition

Product characteristic	OSMITROL profile
Active ingredient	Mannitol
Route	Intravenous infusion
Primary solvent	Water for Injection
Preservative	None
pH adjustment	Hydrochloric acid and/or sodium hydroxide may be used, depending on product presentation
Dosage forms	Sterile injectable solutions
Common concentrations	5%, 10%, 15%, 20%, and 25%
Therapeutic class	Osmotic diuretic
Principal uses	Reduction of intracranial pressure, reduction of intraocular pressure, promotion of urinary excretion
Manufacturer	Baxter Healthcare Corporation

The label identifies mannitol as the active component and Water for Injection as the principal inactive component. The product does not rely on antimicrobial preservatives, surfactants, complex buffering systems, or viscosity modifiers.[1]

Why is the excipient list so short?

Mannitol injection is administered directly into the bloodstream, so every additional excipient creates a potential burden involving compatibility, osmolality, renal handling, toxicity, extractables, leachables, or regulatory review. A minimal composition reduces those risks.

The formulation has three practical requirements:

1. Maintain mannitol in solution during storage and administration.
2. Preserve sterility through terminal processing or aseptic manufacturing.
3. Deliver the intended osmotic load without introducing unnecessary ionic or preservative components.

That simplicity limits formulation patent opportunities but improves generic manufacturability.

What formulation risks affect OSMITROL commercial performance?

The principal technical risk is mannitol crystallization. Mannitol has limited solubility compared with many low-molecular-weight injectable excipients. Solubility declines as temperature falls, which can cause crystals to form during transportation or storage.[2]

Crystallization and cold-chain exposure

A product that appears clear at release can develop visible crystals after exposure to low temperatures. Crystallization can create:

• Administration delays;
• Product rejection by hospital pharmacies;
• Infusion-line obstruction;
• Loss of confidence in the supplier;
• Increased wastage;
• Additional heating or inspection requirements.

Mannitol injection labeling commonly instructs users to inspect the solution for crystals and, where permitted by the label, warm the container to redissolve them before use. The exact handling procedure depends on the presentation and labeling.[1]

Concentration-driven formulation tradeoffs

Higher concentrations increase osmotic activity but also increase crystallization pressure and manufacturing sensitivity.

Mannitol concentration	Commercial and technical implications
5%	Lower osmotic load; may be used where less aggressive osmotic therapy is required; simpler solubility profile
10%	Intermediate concentration with broader fluid-management utility
15%	Higher osmotic effect; greater need for storage and visual-inspection controls
20%	Common hospital concentration for osmotic therapy; meaningful crystallization and vascular-access considerations
25%	Highest listed concentration; strongest logistics, handling, and compatibility requirements

A supplier seeking to compete with OSMITROL should treat concentration selection as a product-design and supply-chain decision, not only as a label-extension exercise.

What excipient strategies can improve a mannitol injection?

The strongest strategy is usually controlled physical formulation rather than aggressive excipient addition. A competitor can pursue five approaches.

Optimize mannitol concentration and pH

pH adjustment can support chemical and physical stability, but excessive buffering may increase ionic load and compatibility concerns. A narrow, justified pH range is preferable to a complex buffer system.

A development program should evaluate:

• Mannitol concentration;
• pH drift during shelf life;
• Crystal formation after refrigerated and freeze-thaw exposure;
• Time to redissolution;
• Particulate generation after warming;
• Container interaction;
• Compatibility with common infusion systems.

Use container technology as a formulation advantage

For a simple aqueous injectable, the container may provide more commercial value than a new excipient. Relevant options include:

• Polyolefin flexible bags;
• Plastic bottles;
• Glass bottles;
• Dual-layer or multilayer films;
• Improved overwraps;
• Small-volume presentations for emergency use;
• Large-volume presentations for institutional supply.

Container selection affects breakage, shipping weight, port design, overwrap requirements, extractables, leachables, and visual inspection.

A flexible bag can reduce breakage and handling costs. A rigid container can improve physical robustness in some hospital settings. The preferred format depends on procurement contracts and installed infusion equipment.

Improve crystallization management

Commercially useful differentiation may include:

• Better control of solution cooling during manufacture;
• More consistent supersaturation control;
• Defined warming instructions;
• Container designs that support visual inspection;
• Packaging that limits exposure to low temperatures;
• Validated shipping profiles;
• Clearer pharmacy handling instructions.

These improvements may be protectable through process, packaging, or use claims, although patentability depends on the specific technical disclosure and demonstrated performance.

Avoid unnecessary excipient complexity

Adding a surfactant, chelator, buffer, or antimicrobial preservative could create more regulatory and clinical issues than value. A new excipient would require justification for intravenous exposure and could complicate comparability with established mannitol injections.

For this product category, the most defensible development position is usually "minimal excipients plus superior physical stability."

What patents protect OSMITROL?

OSMITROL is based on an old small-molecule injectable active ingredient. Mannitol itself is long off patent, and the core composition does not present the type of active-ingredient exclusivity associated with a recently approved drug.

Patent-estate assessment

IP category	OSMITROL relevance	Commercial assessment
Mannitol compound patent	No meaningful current protection expected	Generic entry is technically feasible
Basic aqueous mannitol composition	Likely old or expired technology	Weak barrier
Concentration claims	May exist historically, but broad protection is unlikely to remain enforceable	Limited barrier
Crystallization-control formulation	Potentially relevant only if a specific, unexpired patent exists	Must be verified by jurisdiction
Container and packaging claims	Possible source of narrower protection	Product-specific review required
Manufacturing process claims	Possible but generally design-aroundable	Moderate operational relevance
Method-of-use claims	Therapeutic uses are longstanding	Low expected barrier
Trademark rights	OSMITROL name and branding	Commercial, not composition exclusivity

No current Orange Book patent listing should be assumed from the product name alone. Orange Book status must be checked against the current FDA-listed product, application number, dosage form, and strength.[3] A product can have a marketed brand name without having enforceable formulation or method-of-use patents.

When does OSMITROL lose exclusivity?

OSMITROL's practical exclusivity has already eroded through the age of mannitol and the availability of generic mannitol injection products. The relevant commercial question is not a future loss-of-exclusivity date but the strength of remaining product-specific barriers.

FDA exclusivity and Orange Book considerations

Mannitol injection is an established sterile injectable product rather than a newly protected small-molecule product. The applicable competitive framework generally includes:

• Abbreviated New Drug Applications for generic products;
• Demonstration of pharmaceutical equivalence;
• Compliance with injectable manufacturing requirements;
• Sterility and particulate testing;
• Container-closure and stability data;
• Labeling aligned with the reference product.

The FDA Orange Book identifies patents and exclusivity associated with approved drug applications. For an old injectable such as mannitol, the key review is whether the reference-listed drug has any current listed patent, pediatric exclusivity, or other blocking regulatory protection.[3]

Paragraph IV challenge risk

Paragraph IV risk is structurally low from the innovator perspective because mannitol injection has long been subject to generic competition. It is commercially relevant to any supplier filing a new generic application because the applicant may need to address listed patents if any remain associated with the selected reference product.

A Paragraph IV certification can create patent litigation risk, but the existence of a certification does not establish that a valid patent blocks launch. For OSMITROL, the more material launch risks are likely to be:

• FDA complete-response letters;
• Manufacturing-site readiness;
• Sterile-fill capacity;
• Product-quality observations;
• Supply interruption;
• Crystallization complaints;
• Hospital contract access.

What generic entry risks exist for OSMITROL?

Generic entry risk is high in technical terms and moderate in commercial execution. The product is relatively simple to formulate, but sterile manufacturing and hospital distribution create operational barriers.

Generic launch scenarios

Launch scenario	Likely market effect
Single generic at one concentration	Limited initial price pressure; hospitals may retain dual sourcing
Generic covering 20% and 25% strengths	Greater relevance in critical-care procurement
Full-strength portfolio	Stronger contracting position and substitution potential
Ready-to-use product with improved cold-storage performance	Potential premium or formulary preference
Regional or shortage-driven launch	Opportunity to capture temporary demand
Contract-manufactured hospital product	Lower brand value but possible institutional penetration

The most attractive entry point may be a reliable 20% or 25% presentation with strong supply continuity. A complete concentration portfolio can improve procurement economics but increases validation, inventory, and regulatory burden.

Which companies compete with OSMITROL?

Competition comes from three groups:

1. Generic mannitol injection manufacturers.
2. Large hospital-injection suppliers with flexible bags and broad distribution.
3. Alternative osmotic or hyperosmolar therapies, including hypertonic saline in selected clinical settings.

Potential competitors include Baxter, Fresenius Kabi, Pfizer or its legacy injectable businesses, ICU Medical-affiliated supply channels, and other approved generic manufacturers. The active competitive set changes by concentration, container, country, and temporary shortage conditions.

Brand-level competition is less important than:

• FDA approval status;
• National Drug Code availability;
• Wholesale acquisition cost;
• Contract pricing;
• Back-order history;
• Delivery reliability;
• Container preference;
• Concentration coverage.

How does OSMITROL compare with hypertonic saline?

Mannitol and hypertonic saline are not interchangeable products in every clinical situation. They differ in mechanism, monitoring requirements, contraindications, and institutional protocols.

Attribute	Mannitol injection	Hypertonic saline
Active agent	Mannitol	Sodium chloride
Main osmotic mechanism	Increases plasma osmolality and promotes renal water excretion	Increases serum sodium and osmolality
Excipients	Usually Water for Injection, with pH adjustment	Water for Injection, with sodium chloride and possible pH adjustment
Key formulation issue	Crystallization	Sodium concentration and vascular compatibility
Generic manufacturing barrier	Sterile fill plus crystallization control	Sterile fill plus high-salt formulation control
Commercial differentiation	Concentration, packaging, supply reliability	Concentration range, container, clinical protocol fit

Clinical substitution depends on the indication and institutional practice. A supplier should not assume that a lower price for mannitol will automatically displace hypertonic saline.

What commercial opportunities exist in the OSMITROL market?

The commercial opportunity is centered on reliable supply and product usability rather than novel pharmacology.

Hospital supply and shortage resilience

Hospitals value injectable products that arrive on time and remain usable after routine distribution exposure. A supplier can compete through:

• Multiple manufacturing sites;
• Domestic or regional sterile-fill capacity;
• Temperature-controlled shipping;
• Safety stock;
• Broad concentration coverage;
• Transparent back-order communication;
• Backup container formats.

Shortage periods can create rapid share shifts, but hospitals often restore prior contracts when supply normalizes. Long-term retention requires price, quality, and delivery performance.

Premium packaging

A competitor may secure a premium position with:

• Break-resistant containers;
• Easy-to-spike ports;
• Low-particulate packaging;
• Improved label readability;
• Tamper evidence;
• Unit-dose presentations;
• Storage packaging that reduces cold exposure.

Packaging claims can also support a narrower patent strategy when the design solves a documented crystallization, handling, or compatibility problem.

Contract manufacturing and private-label supply

Mannitol injection is suitable for private-label and contract-manufacturing models because the formulation is established and the clinical use is broad. Opportunities include:

• Regional generic supply;
• Hospital-system private labels;
• Emergency medicine portfolios;
• International tender supply;
• Portfolio bundling with other large-volume injections.

The principal constraints are sterile manufacturing capacity, regulatory approvals, validated container systems, and consistent access to pharmaceutical-grade mannitol.

Geographic expansion

Patent barriers are likely to be less significant than regulatory and market-access requirements outside the United States. Each market may apply different rules to:

• Reference-product selection;
• Bioequivalence or pharmaceutical equivalence;
• Injectable stability;
• Pharmacopoeial standards;
• Local language labeling;
• Import controls;
• Good Manufacturing Practice inspections;
• Hospital tender eligibility.

A single formulation may not support every market because container sizes, concentrations, and labeling conventions differ.

How strong is the OSMITROL patent estate?

The core patent estate is likely weak relative to newer pharmaceutical products. Mannitol is an established active ingredient, and the basic aqueous injection concept is readily reproducible.

The strongest potential IP positions would involve a narrowly defined improvement, such as:

• A composition with verified resistance to crystallization;
• A container that reduces precipitation during transport;
• A manufacturing process that improves solution uniformity;
• A validated warming or administration method;
• A combination of concentration, packaging, and storage conditions.

Broad claims covering "mannitol in water for injection" would face substantial validity and prior-art challenges. A commercially meaningful patent strategy should focus on measurable performance improvements and claims that are difficult to design around.

What FDA regulatory requirements govern a competing mannitol injection?

A competing product would generally require an approved FDA drug application supported by chemistry, manufacturing, and controls data. The development package should address:

• Identity, assay, and impurities;
• Sterility;
• Bacterial endotoxins;
• Visible and subvisible particulate matter;
• Container-closure integrity;
• Extractables and leachables;
• Stability under labeled storage conditions;
• Crystallization and redissolution behavior;
• Manufacturing process validation;
• Shipping and temperature excursions;
• Labeling and instructions for inspection.

For a generic injectable, the regulatory burden is concentrated in product quality and manufacturing control. A reformulated product using novel excipients or a materially different delivery system could require a more complex regulatory pathway.

Key Takeaways

• OSMITROL is a preservative-free mannitol injection with a minimal excipient system.
• The principal formulation challenge is mannitol crystallization during cold storage and transportation.
• Water for Injection and pH adjustment provide the basic excipient platform; unnecessary additives may increase regulatory and compatibility risk.
• The strongest commercial differentiation lies in packaging, storage robustness, concentration coverage, and supply reliability.
• Mannitol has no meaningful current compound-patent barrier in the ordinary generic market.
• Any Orange Book patent or exclusivity conclusion must be tied to the current reference-listed drug and application record.
• Paragraph IV litigation is less important than sterile-manufacturing readiness and FDA product-quality compliance.
• A premium opportunity may exist for a crystallization-resistant, ready-to-use presentation with dependable hospital supply.
• The most defensible new IP would likely cover a specific formulation, container, process, or storage solution rather than mannitol itself.

FAQs

Is OSMITROL preservative-free?

Yes. OSMITROL is labeled as a preservative-free sterile mannitol injection product.[1]

Can mannitol injection be reformulated with a buffer?

It can be evaluated during development, but a buffer is not automatically advantageous. The developer must assess intravenous safety, osmolality, compatibility, stability, and regulatory comparability.

Does mannitol injection require special storage controls?

Yes. Low temperatures can promote crystal formation. The product should be inspected before use and handled according to its approved labeling.[1]

Is there an opportunity for an oral OSMITROL product?

An oral mannitol product would be a different dosage form, clinical-use proposition, and regulatory product. It would not be a simple generic equivalent of intravenous OSMITROL.

What is the main barrier to launching a generic OSMITROL equivalent?

The principal barriers are sterile manufacturing, validated container closure, crystallization control, FDA quality requirements, and reliable hospital distribution rather than active-ingredient patent protection.

References

1. Baxter Healthcare Corporation. (n.d.). OSMITROL (mannitol injection, USP) prescribing information. U.S. Food and Drug Administration labeling database.

2. National Center for Biotechnology Information. (n.d.). Mannitol compound summary. PubChem. https://pubchem.ncbi.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm